Gene therapy breakthroughs for Duchenne muscular dystrophy and ALS in mice

Researchers at MIT used virus‑like nanoparticles called dARC to deliver the CRISPR‑Cas9 gene‑editing system into the muscle of a Duchenne muscular dystrophy mouse model. The treatment enabled exon skipping and restored dystrophin protein expression, demonstrating a new avenue for muscle‑targeted gene delivery.

A separate study from the University of Massachusetts Chan Medical School reported that a single intravenous injection of an engineered AAV9‑based gene‑silencing vector delivering a microRNA against mutant SOD1 extended survival of ALS mice by about 100 days, the most substantial benefit seen with a one‑time therapy in this model. Both advances highlight the potential of viral‑mimicking particles and AAV vectors for treating severe genetic diseases.

These preclinical results suggest possible routes toward more effective, less invasive gene‑therapy treatments for conditions that currently have limited options.